芬戈莫德治疗多发性硬化的中枢神经系统作用机制研究进展  

Direct Central Nervous System Therapeutic Effects of Fingolimod in Multiple Sclerosis

作　　者：谭强[1] 罗家明[1] 余巨明[1] 

机构地区：[1]川北医学院附属医院神经内科,637000

出　　处：《中国临床神经科学》2014年第2期224-227,共4页Chinese Journal of Clinical Neurosciences

基　　金：四川省卫生厅科研课题资助项目(编号:110305)

摘　　要：多发性硬化(MS)是一种中枢神经系统广泛脱髓鞘性自身免疫性疾病,至今无特效治疗方法。芬戈莫德(FTY720)是近年研发的一种能有效治疗复发缓解型MS的新型药物。早前认为抑制淋巴细胞迁移可能是其主要作用机制,新近发现芬戈莫德能直接作用于中枢神经系统,并可能是其治疗MS更为重要的机制。文中就芬戈莫德直接作用于中枢神经系统及其相关机制研究进展作一综述。Multiple sclerosis （MS） is a chronic inflammatory demyelinating disease of the central nervous system （CNS）, which has not be cured yet. Fingolimod（FTY720） is a newly oral disease-modifying therapy approved for RRMS. The mechanism of action of fingolimod in MS has primarily been considered as selectively retaining autoreactive lymphocytes in lymph nodes to reduce damaging infiltration into the CNS. However, emerging evidence indicated that fingolimod has direct effects in the CNS in MS, which may be more important than the former. This review focused on the advances in direct CNS therapeutic effects of fingolimod in MS.

关 键 词：芬戈莫德 多发性硬化 中枢神经系统 自身免疫性疾病 

分 类 号：R744.51[医药卫生—神经病学与精神病学]